IBTA e-News November 2017 released

By 30th November 2017IBTA News
[30 November 2017] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News November 2017 edition in full online here.

Some of the highlights from this month's include:

  • This month has seen Annual Meeting of the Society for Neuro-Oncology and Education Day (SNO 2017) take place in San Francisco, California, USA, from 16th to 19th November, and represents one of the most significant events in the brain tumour research calendar. A summary of some key highlights from the event are covered.
  • A retrospective analysis of a phase III trial (EF-14) of Optune – a wearable Tumor Treating Fields device – in newly diagnosed glioblastoma has demonstrated a link between length of use and clinical effect: patients who used the device more than 90% of the time had the greatest survival (24.9 months),
  • A chemotherapy agent used in ovarian cancer may have the potential to treat brain tumours. According to results from Results the OPARATIC phase I trial of olaparib in glioblastoma, the drug penetrates the tumour mass but not enter unaffected regions of the brain.
  • Results of a small clinical trial provide evidence that a preparation of cannabinoids (CBD:THC) co-administered with the chemotherapy drug temozolomide may improve survival in recurrent glioblastoma.
  • The UK government has announced a new fast-track route into the National Health Service (NHS) for new “breakthrough” medicines and technologies. From April 2018, the new ‘accelerated access pathway’ scheme will mean that new treatments with the greatest potential to change lives could be available up to four years earlier.
  • A phase III clinical trial of Toca 511 and Toca FC, called Toca 5, is now recruiting patients with recurrent high-grade glioma. The treatment involves a targeted viral-based therapy delivered directly into the brain (Toca 511) followed by an oral agent (Toca FC), and the study is being conducted at 67 sites globally.
  • Research published in Genes & Development has shown that (non-WNT) medulloblastoma tumour cells use the amino acid glutamine to grow and multiply. In animal-based experiments, researchers showed that restricting glutamine from the diet worked alongside the chemotherapy agent cisplatin to suppress tumour growth.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

Subscribe to IBTA's e-News!